- Home
- GILD vs PFE Comparison
GILD vs PFE Comparison
Compare GILD & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- PFE
- Stock Information
- Founded
- GILD 1987
- PFE 1849
- Country
- GILD United States
- PFE United States
- Employees
- GILD N/A
- PFE N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- PFE Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- PFE Health Care
- Exchange
- GILD Nasdaq
- PFE Nasdaq
- Market Cap
- GILD 144.1B
- PFE 140.8B
- IPO Year
- GILD 1992
- PFE N/A
- Fundamental
- Price
- GILD $115.05
- PFE $24.88
- Analyst Decision
- GILD Buy
- PFE Hold
- Analyst Count
- GILD 23
- PFE 12
- Target Price
- GILD $115.68
- PFE $29.36
- AVG Volume (30 Days)
- GILD 5.9M
- PFE 36.5M
- Earning Date
- GILD 11-05-2025
- PFE 10-28-2025
- Dividend Yield
- GILD 2.75%
- PFE 6.91%
- EPS Growth
- GILD 496.80
- PFE N/A
- EPS
- GILD 5.01
- PFE 1.89
- Revenue
- GILD $28,863,000,000.00
- PFE $63,833,000,000.00
- Revenue This Year
- GILD $2.01
- PFE $0.39
- Revenue Next Year
- GILD $4.03
- PFE N/A
- P/E Ratio
- GILD $22.96
- PFE $13.17
- Revenue Growth
- GILD 3.81
- PFE 13.53
- 52 Week Low
- GILD $77.74
- PFE $20.92
- 52 Week High
- GILD $121.83
- PFE $30.43
- Technical
- Relative Strength Index (RSI)
- GILD 52.20
- PFE 50.49
- Support Level
- GILD $111.28
- PFE $24.35
- Resistance Level
- GILD $118.13
- PFE $25.12
- Average True Range (ATR)
- GILD 2.06
- PFE 0.41
- MACD
- GILD -0.46
- PFE -0.07
- Stochastic Oscillator
- GILD 39.23
- PFE 30.11
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.